Samanthi A. Perera

机构：Discovery Laboratories (United States) · ORCID：0000-0003-1915-7086

发表论文 124 篇 · 总被引 5633 次 · h-index 20

代表论文

• Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors (2025 · Cancer Research Communications · 被引 5)
• Abstract 7143: Development of a peripheral dazostinag (TAK-676) activation RNASeq signature to evaluate STING pharmacodynamic modulation in human solid tumor clinical trials (2025 · Cancer Research · 被引 2)
• 778 Phase 1b study of dazostinag plus pembrolizumab after hypofractionated radiotherapy in patients with non-small-cell lung cancer, triple-negative breast cancer, or head and neck squamous-cell carcinoma (2024 · Regular and Young Investigator Award Abstracts · 被引 1)
• Discovery of MK-2118, a Small-Molecule Agonist of STING (2026 · ACS Medicinal Chemistry Letters)
• Table 3 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors (2025)
• Figure 3 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors (2025)